PubMed

The NICE ADHD health technology assessment: A review and critique.

Schlander M.

Child Adolesc Psychiatry Ment Health. 2008 Jan 15;2(1):1.PMID: 18197978 [PubMed - in process]Related articlesFree article

Is NICE infallible? A qualitative study of its assessment of treatments for attention-deficit/hyperactivity disorder (ADHD).

Schlander M.

Curr Med Res Opin. 2008 Feb;24(2):515-35.PMID: 18186971 [PubMed - indexed for MEDLINE]Related articles

Has NICE got it right? An international perspective considering the case of Technology Appraisal No. 98 by the National Institute for Health and Clinical Excellence (NICE).

Schlander M.

Curr Med Res Opin. 2008 Apr;24(4):951-66. Epub 2008 Feb 14. Review.PMID: 18279581 [PubMed - indexed for MEDLINE]Related articles

NICE accountability for reasonableness: a qualitative study of its appraisal of treatments for attention-deficit/hyperactivity disorder (ADHD).

Schlander M.

Curr Med Res Opin. 2007 Jan;23(1):207-22.PMID: 17261237 [PubMed - indexed for MEDLINE]Related articles

Procedures and methods of benefit assessments for medicines in Germany.

Bekkering GE, Kleijnen J.

Eur J Health Econ. 2008 Nov;9 Suppl 1:5-29.PMID: 18987905 [PubMed - indexed for MEDLINE]Related articles

[Procedures and methods of benefit assessments for medicines in Germany]

Bekkering GE, Kleijnen J.

Dtsch Med Wochenschr. 2008 Dec;133 Suppl 7:S225-46. Epub 2008 Nov 25. German. PMID: 19034813 [PubMed - indexed for MEDLINE]Related articles

The use of economic evaluations in NHS decision-making: a review and empirical investigation.

Williams I, McIver S, Moore D, Bryan S.

Health Technol Assess. 2008 Apr;12(7):iii, ix-x, 1-175.PMID: 18373906 [PubMed - indexed for MEDLINE]Related articlesFree article

Systematic reviews and economic evaluations conducted for the National Institute for Health and Clinical Excellence in the United Kingdom: a game of two halves?

Drummond MF, Iglesias CP, Cooper NJ.

Int J Technol Assess Health Care. 2008 Spring;24(2):146-50.PMID: 18400116 [PubMed - indexed for MEDLINE]Related articles

Long-acting medications for the hyperkinetic disorders. A note on cost-effectiveness.

Schlander M.

Eur Child Adolesc Psychiatry. 2007 Oct;16(7):421-9. Review.PMID: 17401606 [PubMed - indexed for MEDLINE]Related articles

Atomoxetine: a review of its use in attention-deficit hyperactivity disorder in children and adolescents.

Garnock-Jones KP, Keating GM.

Paediatr Drugs. 2009;11(3):203-26. doi: 10.2165/00148581-200911030-00005. Review.PMID: 19445548 [PubMed - indexed for MEDLINE]Related articles

Assessing the value of atomoxetine in treating children and adolescents with ADHD in the UK.

Prasad S, Arellano J, Steer C, Libretto SE.

Int J Clin Pract. 2009 Jul;63(7):1031-40.PMID: 19570121 [PubMed - in process]Related articles

How should cost-effectiveness analysis be used in health technology coverage decisions? Evidence from the National Institute for Health and Clinical Excellence approach.

Williams I, Bryan S, McIver S.

J Health Serv Res Policy. 2007 Apr;12(2):73-9.PMID: 17407655 [PubMed - indexed for MEDLINE]Related articles

Routine antenatal anti-D prophylaxis for RhD-negative women: a systematic review and economic evaluation.

Pilgrim H, Lloyd-Jones M, Rees A.

Health Technol Assess. 2009 Feb;13(10):iii, ix-xi, 1-103. Review.PMID: 19210896 [PubMed - indexed for MEDLINE]Related articlesFree article

Methodological issues in undertaking independent cost-effectiveness analysis for NICE: the case of therapies for ADHD.

Griffin SC, Weatherly HL, Richardson GA, Drummond MF.

Eur J Health Econ. 2008 May;9(2):137-45. Epub 2007 May 3.PMID: 17476538 [PubMed - indexed for MEDLINE]Related articles

A modelled economic evaluation comparing atomoxetine with methylphenidate in the treatment of children with attention-deficit/hyperactivity disorder in Spain.

Hong J, Dilla T, Arellano J.

BMC Psychiatry. 2009 Apr 14;9:15.PMID: 19366449 [PubMed - indexed for MEDLINE]Related articlesFree article

Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation.

Chen YF, Jobanputra P, Barton P, Bryan S, Fry-Smith A, Harris G, Taylor RS.

Health Technol Assess. 2008 Apr;12(11):1-278, iii. Review.PMID: 18405470 [PubMed - indexed for MEDLINE]Related articlesFree article

Using health outcomes data to inform decision-making: government agency perspective.

Taylor R.

Pharmacoeconomics. 2001;19 Suppl 2:33-8.PMID: 11700787 [PubMed - indexed for MEDLINE]Related articles

Sensitivity analysis in economic evaluation: an audit of NICE current practice and a review of its use and value in decision-making.

Andronis L, Barton P, Bryan S.

Health Technol Assess. 2009 Jun;13(29):iii, ix-xi, 1-61. Review.PMID: 19500484 [PubMed - indexed for MEDLINE]Related articlesFree article

Is ECT cost-effective? A critique of the National Institute of Health and Clinical Excellence's report on the economic analysis of ECT.

McDonald WM.

J ECT. 2006 Mar;22(1):25-9. Review.PMID: 16633202 [PubMed - indexed for MEDLINE]Related articles

A modeled economic evaluation comparing atomoxetine with stimulant therapy in the treatment of children with attention-deficit/hyperactivity disorder in the United Kingdom.

Cottrell S, Tilden D, Robinson P, Bae J, Arellano J, Edgell E, Aristides M, Boye KS.

Value Health. 2008 May-Jun;11(3):376-88.PMID: 18489664 [PubMed - indexed for MEDLINE]Related articles